Oncopeptides drug candidate crosses blood-brain barrier in glioblastoma study

• Oncopeptides presented new results on Oct. 9 from its Insula study in glioblastoma, an aggressive form of brain cancer.
• The drug candidate crossed the blood-brain barrier and reached tumor tissue as expected.
• Patients have tolerated the candidate well so far.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.